Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis And Fudan University To Set Up Cancer Research Lab

This article was originally published in PharmAsia News

Executive Summary

Novartis and Fudan University will jointly conduct research focusing on developing new approaches to understand the causes of cancer. The announcement was made at the groundbreaking ceremony of China Novartis Institutes For Biomedical Research in Shanghai that will accommodate more than 400 researchers in its phase I construction. Researchers from both Novartis Shanghai R&D Center and Fudan will work at a joint lab in the university campus, adopting innovative molecular genetics techniques to develop disease models for new target discovery for cancer therapy. The initial efforts will concentrate on research on liver cancer. (Click here for more - Chinese Language)

You may also be interested in...



Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)

Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel